Interesting alt formulation of rapamycin called “eRapa”, entering phase II trial for treatment of Familial Adenomatous Polyposis. So - maybe the fact that rapamycin is off patent doesn’t rule out the profit motive after all?
“eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035,”
Press release: